Nanofluidics News RSS Feed - Nanofluidics

New Report Analyses International Biochip/Microarray Markets

New Report Analyses International Biochip/Microarray Markets

Research and Markets has announced the addition of a new report "Concise Analysis of the International Biochips and Microarrays Market" to their offering. [More]
3D Microgels May Hold the Key to Personalized Medicine

3D Microgels May Hold the Key to Personalized Medicine

Rather than your average bowl of Lucky Charms, these are three-dimensional cell cultures generated by an exciting new digital microfluidics platform, the results of which have been published in Nature Communications this week by researchers at the University of Toronto. [More]
Researchers Create Living Liquid Crystal

Researchers Create Living Liquid Crystal

Plop living, swimming bacteria into a novel water-based, nontoxic liquid crystal and a new physics takes over. The dynamic interaction of the bacteria with the liquid crystal creates a novel form of soft matter: living liquid crystal. [More]
Comprehensive Analysis of Biochip/Microarray Markets Based on Technologies and Applications

Comprehensive Analysis of Biochip/Microarray Markets Based on Technologies and Applications

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biochips and Microarrays 2014 - Technologies, Markets and Companies" to their offering. [More]
Novel Microfluidic Device for Rapid, Accurate Diagnosis of Pancreatic Cancer

Novel Microfluidic Device for Rapid, Accurate Diagnosis of Pancreatic Cancer

Pancreatic cancer is a particularly devastating disease. At least 94 percent of patients will die within five years, and in 2013 it was ranked as one of the top 10 deadliest cancers. [More]
Scientists Design Endothelialized Microfluidic Device for Testing Nanomedicine

Scientists Design Endothelialized Microfluidic Device for Testing Nanomedicine

Designing nanomedicine to combat diseases is a hot area of scientific research, primarily for treating cancer, but very little is known in the context of atherosclerotic disease. Scientists have engineered a microchip coated with blood vessel cells to learn more about the conditions under which nanoparticles accumulate in the plaque-filled arteries of patients with atherosclerosis, the underlying cause of myocardial infarction and stroke. [More]
UT Arlington Researcher Proves Importance of Mass at Nano-Scale

UT Arlington Researcher Proves Importance of Mass at Nano-Scale

A UT Arlington engineering professor has proven that the effect of mass is important, can be measured and has a significant impact on any calculations and measurements at the sub-micrometer scale. [More]
Researchers Model Explains Macroscale Fluid Convection Induced by Plasmonic Nanostructures

Researchers Model Explains Macroscale Fluid Convection Induced by Plasmonic Nanostructures

Researchers at the University of Illinois at Urbana-Champaign have developed a new theoretical model that explains macroscale fluid convection induced by plasmonic (metal) nanostructures. Their model demonstrates the experimentally observed convection velocities of the order of micrometers per second for an array of gold bowtie nanoantennas (BNAs) coupled to an optically absorptive indium-tin-oxide (ITO) substrate. [More]
Advent of Nano-Biotechnologies Involving Nano-Fluidics Will Boost Life Sciences and Bioengineering

Advent of Nano-Biotechnologies Involving Nano-Fluidics Will Boost Life Sciences and Bioengineering

Research and Markets has announced the addition of the "National Innovation Ecosystems: Healthcare, CMF, Energy - Technical Insights" report to their offering. [More]
Spinomix and Debiopharm Report Second Development Milestone on MagPhase and FibroTrap Technologies

Spinomix and Debiopharm Report Second Development Milestone on MagPhase and FibroTrap Technologies

Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the successful achievement of a second development milestone on Spinomix' two proprietary technologies, namely MagPhase™ and FibroTrap™. In conjunction with the terms of the investment agreement, Spinomix is to receive an undisclosed second tranche payment from Debiopharm. [More]
Site Sponsors
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D